Novel diagnostic approaches in TB  and MDR-TB and biomarkers of treatment response

Leading partner organisation: Imperial College (UK)

Tuberculosis (TB) causes 10.4 million new cases globally. In order to comprehensively improve the clinical and epidemiological management of tuberculosis, particularly in Eastern European regions, CARE will focus on:

  • Identification of biomarkers of drug-sensitive and MDR-TB and association with treatment failure/cure by analysing blood/plasma and urine in a longitudinal treatment cohort

  • Development of non-invasive early TB diagnostics and definition of prognostic markers based on urine analysis

  • Definition of novel biomarkers of TB disease progression or cure, particularly in the context of multidrug resistant TB (MDR-TB)

  • Investigation of the role of SIGLEC 1 in TB by identifying and analysing polymorphisms in an extra-pulmonary TB cohort

Heading 1

Heading 1

Heading 1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.

Subscribe to the CARE newsletter

Francesca Incardona